da-6886
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01633723)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serotonin 4 (5-HT4) receptorAGONIST
HTR4 agonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(N)c(Cl)cc1C(=O)NCC1CCN(CCCn2ccnn2)CC1- Mol. weight
- 406.92 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3950712 ↗
Also known as
- da-6886
- da-6886
- da-6886
- da-6886
- n-((1-(3-(1,2,3-triazol-1-yl)propyl)piperidin-4-yl)methyl)-4-amino-5-chloro-2-methoxybenzamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01633723 | Phase 1 | Aug 1, 2012 | Dong-A Pharmaceutical |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dong-A Pharmaceutical | For profit | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1